HC Wainwright restated their buy rating on shares of Dyadic International (NASDAQ:DYAI – Free Report) in a report issued on Thursday morning,Benzinga reports. The firm currently has a $6.00 price objective on the biotechnology company’s stock.
Dyadic International Stock Down 0.9 %
DYAI opened at $1.13 on Thursday. Dyadic International has a 12 month low of $0.93 and a 12 month high of $2.67. The company has a debt-to-equity ratio of 1.54, a current ratio of 5.15 and a quick ratio of 5.39. The stock has a market cap of $33.43 million, a P/E ratio of -4.91 and a beta of 0.72. The stock’s 50 day moving average price is $1.12 and its 200 day moving average price is $1.42.
Dyadic International (NASDAQ:DYAI – Get Free Report) last posted its earnings results on Tuesday, November 12th. The biotechnology company reported ($0.01) EPS for the quarter, beating the consensus estimate of ($0.07) by $0.06. Dyadic International had a negative return on equity of 149.16% and a negative net margin of 188.09%. The firm had revenue of $1.96 million for the quarter, compared to analysts’ expectations of $1.05 million. During the same period last year, the firm earned ($0.06) EPS. As a group, research analysts predict that Dyadic International will post -0.28 earnings per share for the current year.
Institutional Trading of Dyadic International
Dyadic International Company Profile
Dyadic International, Inc, a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health.
Read More
- Five stocks we like better than Dyadic International
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- ORIC: Working with Two Pharma Giants, Analysts See +100% Upside
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Freeport-McMoRan, Copper Demand Short-Term Pain, Long-Term Gain
- Which Wall Street Analysts are the Most Accurate?
- Time to Load Up on Home Builders?
Receive News & Ratings for Dyadic International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dyadic International and related companies with MarketBeat.com's FREE daily email newsletter.